A Study to Evaluate Real World Outcomes of the enVista® Aspire (EA) and Aspire Toric (ETA) Intraocular Lens in Subjects Undergoing Cataract Extraction

Inclusion Criteria:

1. 22 years of age or older on the date the Informed Consent Form (ICF) is signed.

2. Subjects must be capable of understanding and providing informed consent on theInstitutional Review Board (IRB)- approved Informed Consent Form (ICF) andauthorization as appropriate for local privacy regulations.

3. Have a BCDVA at or worse than 20/40 in each eye, with or without a glare source, dueto a clinically significant cataract (cortical, nuclear, subcapsular, orcombination) that is considered amenable to treatment with standardphacoemulsification cataract extraction and capsular IOL implantation.

4. Have a BCDVA projected to be better than 20/30 after IOL implantation in each eye asdetermined by the medical judgment of the Principal Investigator.

5. Subjects must have clear intraocular media other than the cataract in both eyes.

6. Subjects must require an IOL power from +6.0 diopter (D) to +34.0 diopter (D) inboth eyes.

7. Subjects with clinically significant preoperative corneal astigmatism must requirean IOL toric power between 1.25 diopter (D) to 5.75 diopter (D).

8. Subjects must be willing and able to comply with all treatment and follow-upClinical Investigation visits and procedures

Exclusion Criteria:

1. Pre-existing ocular conditions (subjects with prior corneal refractive surgery,irregular corneal astigmatism, severe (clinically significant) corneal dystrophy,e.g., Fuch's, macular disease, optic nerve atrophy, corneal endothelial disease,abnormal cornea, macular degeneration, retinal degeneration, and chronic drugmiosis, who may not achieve the visual acuity of patients without such problems,etc.)

2. Associated ocular conditions that could affect the stability of the IOL (e.g.,traumaticzonulolysis, zonular dialysis, evident zonular weakness or dehiscence,etc.) in the study eye.

3. Retinal conditions, or predisposition to retinal conditions, previous history of, ora predisposition to, retinal detachment or proliferative diabetic retinopathy, inwhich future treatment may be compromised by implanting this IOL

4. Amblyopia

5. Rubella, congenital, traumatic, or complicated cataracts

6. Extremely shallow anterior chamber, not due to swollen cataract

7. Recurrent anterior or posterior segment inflammation of unknown etiology, or anydisease producing an inflammatory reaction (e.g., iritis or uveitis)

8. Aniridia

9. Iris neovascularization

10. Subjects who have uncontrolled glaucoma in either eye. Uncontrolled glaucoma isdefined as intraocular pressure (IOP) greater than 21 mm Hg in spite of maximallytolerated medications (with more than three topical drugs for IOP control).

11. Microphthalmos or macrophthalmos

12. Previous corneal transplant, prior YAG laser iridotomy, YAG vitreolysis, and priorphakic IOL insertions.

13. Pre-existing ocular conditions that may negatively impact the stability of theimplant or intraoperative conditions (posterior capsular rupture, complications inwhich the IOL stability could be compromised, inability to place IOL in capsularbag, etc.).

14. Mechanical or surgical manipulation required to enlarge the pupil

15. Vitreous loss (significant)

16. Anterior chamber bleeding (significant)